ABSTRACT NUMBER: ESOC2026A447 EFFICACY AND SAFETY OF TAFOLECIMAB IN PATIENTS WITH CEREBROVASCULAR DISEASE AND HYPERCHOLESTEROLEMIA: A POST-HOC ANALYSIS OF POOLED DATA FROM THREE PHASE 3 TRIALS
Hua Shen, Litong Qi, Meng Chai, Lei Qian, Jianwei Zhang, Haoyu Li, Yujie Zhou, Yong Huo · 2026
Read ABSTRACT NUMBER: ESOC2026A447 EFFICACY AND SAFETY OF TAFOLECIMAB IN PATIENTS WITH CEREBROVASCULAR DISEASE AND HYPERCHOLESTEROLEMIA: A POST-HOC ANALYSIS OF POOLED DATA FROM THREE PHASE 3 TRIALS by Hua Shen, Litong Qi, Meng Chai, Lei Qian, Jianwei Zhang, Haoyu Li, Yujie Zhou, Yong Huo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13145423.txt.
Description
Hua Shen and co-authors pool data from three phase 3 trials to test a cholesterol-lowering antibody in patients who have both blood-vessel disease in the brain and high cholesterol. Such patients face a high risk of another stroke or vascular event. The drug, tafolecimab, blocks a protein called PCSK9 and had already cut LDL cholesterol in broader patient groups.
The analysis covers 148 patients with cerebrovascular disease, 106 on the drug and forty-two on placebo, dosed every four weeks. At twelve weeks, LDL cholesterol had fallen by about sixty-two percent on the drug while rising slightly on placebo. Nearly all treated patients reached the target cholesterol level, versus a small share on placebo. Side effects occurred at similar rates in both groups, with none serious and tied to the drug.
Catalog record
| CREATOR | Hua Shen, Litong Qi, Meng Chai, Lei Qian, Jianwei Zhang, Haoyu Li, Yujie Zhou, Yong Huo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |